The Impact of Early Iron Supplementation on Neurodevelopmental Outcomes in Infants: A Meta-analysis
DOI:
https://doi.org/10.54361/LJMR.19.2.46Keywords:
Iron Supplementation, Neurodevelopment, Infants, Meta-analysisAbstract
Background: Iron deficiency during the critical window of early life can adversely affect long-term brain development. This systematic review and meta-analysis aimed to quantitatively evaluate the impact of early iron supplementation on neurodevelopmental outcomes in infants to inform clinical practice. Material and Methods: We systematically searched PubMed, Cochrane, and Embase databases from inception to May 2025. We selected randomized controlled trials (RCTs) evaluating iron supplementation in infants aged 0–24 months that reported neurodevelopmental outcomes. The primary outcome measured was the Mental Development Index (MDI), while secondary outcomes included iron status parameters and behavioral assessments. We assessed risk of bias using the Cochrane tool and evaluated the overall quality of evidence using GRADE criteria. Results: Fourteen studies met the inclusion criteria for qualitative synthesis; eight studies (n=561 infants) were eligible for meta-analysis. Iron supplementation was associated with significant improvements in MDI scores (Mean Difference [MD] 2.27; 95% CI: 1.43 to 3.12; I²=18%). Subgroup analyses revealed substantially greater benefits in preterm and low birth weight infants (MD 3.1; 95% CI: 1.8 to 4.4) compared to term infants (MD 1.2; 95% CI: 0.3 to 2.1). Interventions starting earlier (0–3 months) showed greater neurodevelopmental benefits than those starting later (4–6 months). Additionally, supplementation significantly reduced externalizing behavioral problems (Risk Ratio [RR] 0.36; 95% CI: 0.17 to 0.76) and improved hemoglobin levels (MD 0.42 g/dL). Adverse events were rare, with only constipation showing a significant increase (RR 1.23; 95% CI: 1.02 to 1.49). Conclusion: Early iron supplementation positively impacts neurodevelopmental outcomes, with the most pronounced benefits observed in high-risk groups such as preterm and low birth weight infants. Crucially, the timing of supplementation appears vital, with earlier intervention yielding superior cognitive results. These findings strongly support current recommendations for iron supplementation in infancy, specifically prioritizing at-risk populations.
Downloads
References
1. World Health Organization. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015.
2. Domellöf M, Braegger C, Campoy C, et al. Iron requirements of infants and toddlers. J Pediatr Gastroenterol Nutr. 2014;58(1):119-129.
3. Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. Lancet Glob Health. 2013;1(1):e16-e25.
4. Georgieff MK. Iron assessment to protect the developing brain. Am J Clin Nutr. 2017;106(Suppl 6):1588S-1593S.
5. Lozoff B, Georgieff MK. Iron deficiency and brain development. Semin Pediatr Neurol. 2006;13(3):158-165.
6. Bastian TW, von Hohenberg WC, Mickelson DJ, Georgieff MK, Rao R. Iron deficiency impairs developing hippocampal neuron gene expression, energy metabolism, and dendrite complexity. Dev Neurosci. 2016;38(4):264-276.
7. Baker RD, Greer FR; Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010;126(5):1040-1050.
8. World Health Organization. Guideline: Daily iron supplementation in infants and children. Geneva: World Health Organization; 2016.
9. Domellöf M, Jonsson B, Bogen DL, et al. Enteral iron supplementation in preterm and low birth weight infants: a systematic review and meta-analysis. Nutrients. 2019;11(5):1090.
10. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T. Long-lasting neural and behavioral effects of iron deficiency in infancy. Nutr Rev. 2006;64(5 Pt 2):S34-S43.
11. Berglund SK, Westrup B, Hägglöf B, Hernell O, Domellöf M. Effects of iron supplementation of LBW infants on cognition and behavior at 3 years. Pediatrics. 2013;131(1):47-55.
12. Friel JK, Aziz K, Andrews WL, Harding SV, Courage ML, Adams RJ. A double-masked, randomized control trial of iron supplementation in early infancy in healthy term breast-fed infants. J Pediatr. 2003;143(5):582-586.
13. Lind T, Lönnerdal B, Stenlund H, et al. A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: effects on growth and development. Am J Clin Nutr. 2004;80(3):729-736.
14. Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. Lancet Glob Health. 2013;1(2):e77-e86.
15. Thompson J, Biggs BA, Pasricha SR. Effects of daily iron supplementation in 2- to 5-year-old children: systematic review and meta-analysis. Pediatrics. 2013;131(4):739-753.
16. Wang B, Zhan S, Gong T, Lee L. Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anaemia. Cochrane Database Syst Rev. 2013;(6):CD001444.
17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
18. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
19. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
23. Lozoff B, Jimenez E, Hagen J, Mollen E, Wolf AW. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics. 2000;105(4):E51.
24. Leung BMY, Wiens KP, Kaplan BJ. Does prenatal micronutrient supplementation improve children's mental development? A systematic review. BMC Pregnancy Childbirth. 2011;11:12.
25. Rao R, Georgieff MK. Iron therapy for preterm infants. Clin Perinatol. 2009;36(1):27-42.
26. Beard JL, Connor JR. Iron status and neural functioning. Annu Rev Nutr. 2003;23:41-58.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nouri Mumash, Ahmed S. Mikeal, Mohammed M. Makhzom3, Ibrahim M. Altaib, Ebtihaj S. Durman, Asmaa M. Aqoub, Abdulnasir J. Yunus, Jamal A. Bilrrahal (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.









